The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Biomarker-driven selection of BCMA- and GPRC5D-directed therapies in multiple myeloma
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, discusses the potential of biomarker-driven target selection to guide the use of BCMA- and GPRC5D-directed therapies in multiple myeloma. Dr Hansen highlights that, while validated biomarkers are not yet available for treatment selection in routine clinical practice, they could ultimately enable more personalized treatment selection and help ensure the right therapies reach the right patients at the right time. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I do think that we are getting much closer biologically, but we’re not yet at the point where I routinely use a biomarker to really guide antigen selection at this time. We’re learning a lot about mechanisms of resistance, whether that might be antigen loss or mutation, antigen downregulation, T cell fitness, or other aspects of tumor and immune biology. But we still need prospectively validated biomarkers or assays that can reliably tell us which antigen or therapy would a patient be most likely to benefit at a certain time...
I do think that we are getting much closer biologically, but we’re not yet at the point where I routinely use a biomarker to really guide antigen selection at this time. We’re learning a lot about mechanisms of resistance, whether that might be antigen loss or mutation, antigen downregulation, T cell fitness, or other aspects of tumor and immune biology. But we still need prospectively validated biomarkers or assays that can reliably tell us which antigen or therapy would a patient be most likely to benefit at a certain time. So ultimately, I would want us to have a molecular or functional profile when we are making major treatment decisions for our patients and use that information to help us select the right target and the right therapy at the right time. But currently, we’re still largely sequencing based on prior therapies, clinical disease characteristics, access, and toxicity, although I do believe that the future very much will be biology and biomarker driven to help us personalize treatment for each and all of our patients with multiple myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
